Compare Southwest Airlines Co (LUV) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Southwest Airlines Co trades at $39.3 (market cap $19.89B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Southwest Airlines Co is far larger — about 20.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Southwest Airlines Co pays a 1.77% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 66 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LUV | MRVI | |
|---|---|---|
Market Cap | $19.89B | $972.90M |
Volume | 3,985,163 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $54.80 | $9.00 |
52-Week Low | $29.67 | $2.83 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $22.98B | $1.08B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $39.34, down 3.48% today, showing bearish technical signals with mixed earnings performance. The company reported a Q2 2026 EPS beat ($0.94 vs $0.51 expected) but missed Q1 expectations. Fundamentals show modest revenue growth to $28.06B in 2025 with a thin 2.78% net margin, though valuation appears reasonable with P/S of 0.71 and P/E of 25.41. Recent news highlights Southwest's commercial transformation initiatives targeting over $2B EBIT in 2026.
LUV presents a turnaround opportunity with analyst consensus target of $49.61 offering 26% upside, though near-term headwinds from high fuel costs and competitive pressures persist. The stock's bearish technical setup and volatile earnings history require careful risk management, but successful execution of revenue initiatives could drive significant shareholder value.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
